15,000 Shares in Celcuity, Inc. $CELC Purchased by Aristides Capital LLC

Aristides Capital LLC acquired a new position in Celcuity, Inc. (NASDAQ:CELC) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,000 shares of the company’s stock, valued at approximately $741,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Creative Planning purchased a new stake in shares of Celcuity in the 2nd quarter worth approximately $177,000. Intech Investment Management LLC grew its stake in shares of Celcuity by 5.2% in the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after acquiring an additional 734 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Celcuity during the second quarter valued at $169,000. Finally, Saturn V Capital Management LP increased its holdings in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after acquiring an additional 91,843 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

NASDAQ CELC opened at $110.77 on Friday. Celcuity, Inc. has a one year low of $7.57 and a one year high of $120.32. The stock has a 50-day moving average of $108.52 and a 200 day moving average of $86.38. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The company has a market capitalization of $5.13 billion, a price-to-earnings ratio of -30.18 and a beta of 0.38.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.77% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CELC shares. Craig Hallum upped their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wolfe Research restated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday. Wells Fargo & Company started coverage on shares of Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price on the stock. Needham & Company LLC increased their price target on shares of Celcuity from $95.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $108.63.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.